Bloomage BioTechnology Corporation Limited (SHA:688363)
China · Delayed Price · Currency is CNY 43.00
-0.96 (-2.18%)
At close: Mar 20, 2026
SHA:688363 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,217 | 5,361 | 6,075 | 6,359 | 4,947 |
Other Revenue | - | 9.49 | 0.6 | 0.41 | 0.55 |
| 4,217 | 5,371 | 6,076 | 6,359 | 4,948 | |
Revenue Growth (YoY) | -21.49% | -11.61% | -4.45% | 28.53% | 87.93% |
Cost of Revenue | - | 1,482 | 1,659 | 1,482 | 1,118 |
Gross Profit | 4,217 | 3,889 | 4,417 | 4,877 | 3,829 |
Selling, General & Admin | - | 3,118 | 3,331 | 3,439 | 2,736 |
Research & Development | - | 466.25 | 446.35 | 388.19 | 284.34 |
Other Operating Expenses | 3,883 | 46.48 | 62.01 | 73.25 | 56.95 |
Operating Expenses | 3,883 | 3,656 | 3,847 | 3,915 | 3,083 |
Operating Income | 333.9 | 232.36 | 570.18 | 961.48 | 746.46 |
Interest Expense | - | -9.17 | -10.74 | -14.52 | -11.08 |
Interest & Investment Income | - | 14.11 | 39.78 | 50.44 | 45.07 |
Currency Exchange Gain (Loss) | - | 2.97 | 3.9 | 25.19 | -12.05 |
Other Non Operating Income (Expenses) | -0.11 | -4.76 | 1.71 | -3.88 | -2.62 |
EBT Excluding Unusual Items | 333.79 | 235.51 | 604.84 | 1,019 | 765.77 |
Impairment of Goodwill | - | -74.09 | - | - | - |
Gain (Loss) on Sale of Investments | - | -11.48 | -18.74 | -0.14 | 7.39 |
Gain (Loss) on Sale of Assets | - | -0.11 | -3.42 | -0.24 | 0.04 |
Asset Writedown | - | -0.86 | -1.87 | -0.53 | -3.91 |
Other Unusual Items | - | 64.43 | 120.91 | 118.32 | 120.9 |
Pretax Income | 333.79 | 213.39 | 701.72 | 1,136 | 890.2 |
Income Tax Expense | 42.72 | 44.99 | 118.98 | 174.73 | 114.64 |
Earnings From Continuing Operations | 291.07 | 168.41 | 582.74 | 961.38 | 775.56 |
Minority Interest in Earnings | - | 5.86 | 9.81 | 9.54 | 6.78 |
Net Income | 291.07 | 174.27 | 592.56 | 970.92 | 782.33 |
Net Income to Common | 291.07 | 174.27 | 592.56 | 970.92 | 782.33 |
Net Income Growth | 67.03% | -70.59% | -38.97% | 24.10% | 21.14% |
Shares Outstanding (Basic) | 477 | 484 | 482 | 481 | 480 |
Shares Outstanding (Diluted) | 477 | 484 | 482 | 483 | 483 |
Shares Change (YoY) | -1.43% | 0.48% | -0.27% | 0.03% | 0.95% |
EPS (Basic) | 0.61 | 0.36 | 1.23 | 2.02 | 1.63 |
EPS (Diluted) | 0.61 | 0.36 | 1.23 | 2.01 | 1.62 |
EPS Growth | 69.44% | -70.73% | -38.81% | 24.07% | 20.00% |
Free Cash Flow | - | -156.88 | -330.68 | -61.22 | 491.85 |
Free Cash Flow Per Share | - | -0.32 | -0.69 | -0.13 | 1.02 |
Dividend Per Share | - | 0.110 | 0.380 | 0.610 | 0.490 |
Dividend Growth | - | -71.05% | -37.70% | 24.49% | 19.51% |
Gross Margin | 100.00% | 72.41% | 72.69% | 76.69% | 77.40% |
Operating Margin | 7.92% | 4.33% | 9.38% | 15.12% | 15.09% |
Profit Margin | 6.90% | 3.25% | 9.75% | 15.27% | 15.81% |
Free Cash Flow Margin | - | -2.92% | -5.44% | -0.96% | 9.94% |
EBITDA | 567 | 465.45 | 775.49 | 1,124 | 866.92 |
EBITDA Margin | 13.45% | 8.67% | 12.76% | 17.68% | 17.52% |
D&A For EBITDA | 233.1 | 233.1 | 205.31 | 162.69 | 120.46 |
EBIT | 333.9 | 232.36 | 570.18 | 961.48 | 746.46 |
EBIT Margin | 7.92% | 4.33% | 9.38% | 15.12% | 15.09% |
Effective Tax Rate | 12.80% | 21.08% | 16.96% | 15.38% | 12.88% |
Revenue as Reported | - | 5,371 | 6,076 | 6,359 | 4,948 |
Advertising Expenses | - | 1,377 | 1,790 | 2,051 | 1,583 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.